New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on November 13, 2018

Nov 07, 2018, 16:15 ET

CRANBURY, N.J., Nov. 7, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2019 operating results on Tuesday, November 13, 2018 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 13, 2018 at 11:00 a.m. ET. The conference call will include a review of the company’s operating results and an update on programs under development.

Schedule for the Operating Results Press Release, Conference Call / Audio Webcast



Q1 Fiscal Year 2019 Financial Results Press Release         

11/13/2018 at 7:30 a.m. ET



Q1 Fiscal Year 2019 Conference Call-Live                         

11/13/2018 at 11:00 a.m. ET

US/Canada Dial-In Number:                                          

1-877-260-1479

International Dial-In Number:                                          

1-334-323-0522

Conference ID:                                                               

5988704



Q1 Fiscal Year 2019 Conference Call-Replay                  

11/13/2018-11/20/2018

US/Canada Dial-In Number:                                             

1-888-203-1112

International Dial-In Number:                                     

1-719-457-0820

Replay Passcode:                                                     

5988704



Audio Webcast Live and Replay Access                       

http://www.palatin.com

The audio webcast and replay can be accessed by logging on to the “Investors-Webcasts” section of Palatin’s website at http://www.palatin.com.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information, please visit http://www.palatin.com.

SOURCE Palatin Technologies, Inc.

Related Links

http://www.palatin.com

Scroll to Top